DUBLIN, Oct. 16, 2016 /PRNewswire/ -- Allergan plc (NYSE:
AGN) announced today the formation of the IBS CounSEL, a group of
multidisciplinary experts dedicated to improving diagnosis and
management of irritable bowel syndrome (IBS) by providing Support,
Education and Leadership (SEL) to physicians and allied healthcare
professionals. The IBS CounSEL will launch their new website at the
American College of Gastroenterology (ACG) Annual Scientific
Meeting from October 14-19, 2016 in
Las Vegas.
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
IBS is a chronic gastrointestinal disorder associated with
disturbances of intestinal motility, sensation, and secretion,
resulting in recurrent abdominal pain and changes in bowel
habits.i,ii
This chronic disorder affects an
estimated 35 million Americans and is associated with impaired
quality of life, significant disability and emotional distress, and
high healthcare costs.iii,iv,v,vi
The American Gastroenterological Association's recent "IBS in
America" survey found that when physicians were asked what is
lacking most in the treatment of IBS, the second-most-common answer
was communication between doctors and patients. With this in mind,
Allergan looked to bring together healthcare professionals to
develop practical tools and provide expert guidance for physicians
and allied healthcare professionals in the diagnosis and management
of IBS.
"The IBS CounSEL was created to fill the necessary need for
continued informed dialogue between IBS patients and their
physicians," said Dr. Susan Lucak,
Chair of The IBS CounSEL. "It's important in any medical discipline
that we continue to hone our craft based on the latest information
available. The IBS CounSEL is a group of healthcare professionals
who are looking to do just that."
As part of their commitment to improving IBS education, the
organization developed an interactive website. In addition to
providing disease-state information, simple downloadable resources
are available through diagnosis and management toolkits.
The IBS CounSEL will have a booth on-site from October
16 -18 during the ACG Annual Scientific Meeting where the
website will be demonstrated.
For additional information on IBS and to learn more about the
IBS CounSEL, please visit www.ibscounsel.com.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin,
Ireland, is a bold, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing,
manufacturing and commercializing branded pharmaceuticals, devices
and biologic products for patients around the world.
Allergan markets a portfolio of leading brands and
best-in-class products for the central nervous system, eye care,
medical aesthetics and dermatology, gastroenterology, women's
health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the
Company's R&D model, which defines our approach to identifying
and developing game-changing ideas and innovation for better
patient care. This approach has led to Allergan building
one of the broadest development pipelines in the pharmaceutical
industry with 65+ mid-to-late stage pipeline programs in
development.
Our Company's success is powered by our more than 16,000 global
colleagues' commitment to being Bold for Life. Together, we
build bridges, power ideas, act fast and drive results for our
customers and patients around the world by always doing what is
right.
With commercial operations in approximately 100
countries, Allergan is committed to working with
physicians, healthcare providers and patients to deliver innovative
and meaningful treatments that help people around the world live
longer, healthier lives.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective of existing trends
and information as of the date of this release. Except as expressly
required by law, Allergan disclaims any intent or
obligation to update these forward-looking statements. Actual
results may differ materially from Allergan's current
expectations depending upon a number of factors
affecting Allergan's business. These factors include,
among others, the difficulty of predicting the timing or outcome
of FDA approvals or actions, if any; the impact of
competitive products and pricing; market acceptance of and
continued demand for Allergan's products; difficulties or
delays in manufacturing; and other risks and uncertainties detailed
in Allergan's periodic public filings with
the Securities and Exchange Commission, including but not
limited to Allergan's Annual Report on Form 10-K for the
year ended December 31, 2015 and Quarterly Report on Form
10-Q for the quarter ended June 30, 2016 (certain of such
periodic public filings having been filed under the "Actavis plc"
name). Except as expressly required by
law, Allergan disclaims any intent or obligation to
update these forward-looking statements.
i Longstreth GF et al. Gastroenterology 2006;
130: 1480-1491.
ii Ford AC et al. Am J Gastroenterol 2014; 109 (Suppl
1): S2-26.
iii Canavan C et al. Clin Epidemiol 2014; 6: 71-80
iv Saito YA et al. Am J Gastroenterol 2002; 97:
1910-1915.
v Drossman DA et al. Gastroenterology 2002; 123:
2108-2131.
vi Hulisz D. J Manag Care Pharm 2004; 10: 299-309.
CONTACT: Media:
Fran
DeSena
(973) 517-3132
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/allergan-demonstrates-ongoing-commitment-to-irritable-bowel-syndrome-ibs-with-development-of-ibs-counsel-300345466.html
SOURCE Allergan plc